Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Is Ozempic a game-changer for insulin resistance? What you need to know
SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.
The Lancet3d
Increasing walking capacity in patients with peripheral artery disease
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® ...
Clinical Advisor8d
Could GLP-1RAs be a Novel Pharmacological Intervention for AUD?
Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Mena FN3d
SCORE Analysis Of Semaglutide 2.4 Mg Demonstrated Reduction In Cardiovascular Events In A Real-World Setting
25). 1 "Real-world analyses such ... 1 Revised MACE-5 occurred in 88 (0.94%) of the 9,321 patients in the semaglutide 2.4 mg group and 288 (1.54%) of 18,642 patients in the non-user group.